



Attorney Docket No.: 6124.200-US

RECEIVED
JUL 24 2001
TECH CENTER 1600/2900
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Arentsen

Serial No.: 09/769,692

Group Art Unit: 1614

Filed: January 25, 2001

Examiner: To be assigned

Confirmation No: 5360

For: Crystallisation Of A GLP-1 Analogue

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on 17 July 2001.

Sylvia Gonzalez
(name of person mailing paper)

(signature of person mailing paper)



Attorney Docket No.: 6124.200-US

PATENT
TECH CENTER 1600/2900
JUL 24 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Arentsen

Application No.: 09/769,692

Group Art Unit: 1614

Filed: January 25, 2001

Examiner: To be assigned

Confirmation No: 5360

For: Crystallisation Of A GLP-1 Analogue

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. WO 99/30731
2. WO 99/43708
3. EP 0 619 322 A2


4.. Lone Pridal et al., "Absorption of glucagons-like peptide-1 can be protracted by zinc or protamine". Int'l Journal of Pharmaceutics, Vol. 136, pages 53-59 (1996)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: 17 July 2001



Valeta A. Gregg

Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



FORM PTO-1449
(Rev. 2-32)

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6124.200-US

Serial No. 09/769,692

JUL 20 2001

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Arentsen

Filing Date January 25, 2001

Group 1614

ECH CENTER

JUL 24 2000

RECEIVED

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Lone Pridal et al: "Absorption of glucagons-like peptide-1 can be protracted by zinc or protamine" - International Journal of Pharmaceutics Vol. 136, pages 53-59 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.